Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Headlands Technologies LLC

Key Points

• Headlands Technologies LLC reduced its stake in Regeneron Pharmaceuticals by 37%, now holding 3,394 shares valued at $2,153,000 as of its latest SEC filing.
• Regeneron Pharmaceuticals recently reported earnings of $12.89 per share, significantly surpassing the consensus estimate of $8.43, while the company's revenue increased by 3.6% year-over-year.
• The stock has a market cap of $59.93 billion and an average consensus target price set at $841.30, with various analysts giving it a "Moderate Buy" rating.

Headlands Technologies LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 37.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,394 shares of the biopharmaceutical company's stock after selling 1,997 shares during the quarter. Headlands Technologies LLC's holdings in Regeneron Pharmaceuticals were worth $2,153,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Adirondack Trust Co. boosted its position in shares of Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after buying an additional 18 shares in the last quarter. Kingswood Wealth Advisors LLC raised its stake in Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after purchasing an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV raised its stake in Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after purchasing an additional 19 shares during the last quarter. Private Trust Co. NA raised its stake in Regeneron Pharmaceuticals by 13.1% in the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 19 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its stake in Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 19 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $555.13 on Thursday. The company has a current ratio of 4.60, a quick ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market cap of $59.93 billion, a P/E ratio of 13.99, a P/E/G ratio of 2.08 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The stock's 50 day simple moving average is $536.31 and its 200 day simple moving average is $601.45.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The business's revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company posted $11.56 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Analysts Set New Price Targets

REGN has been the subject of a number of research analyst reports. Canaccord Genuity Group reaffirmed a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Bank of America decreased their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. Finally, Citigroup restated a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $841.30.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.